Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GB 261

Next Previous
Drug Profile

GB 261

Alternative Names: CD3×CD20 bi-specific antibody - Genor Biopharma; CND-261; GB-261

Latest Information Update: 17 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genor Biopharma
  • Developer Candid Therapeutics; Genor Biopharma
  • Class Antineoplastics; Antirheumatics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Phase I Rheumatoid arthritis
  • Clinical Phase Unknown Systemic scleroderma

Most Recent Events

  • 31 Jan 2026 Candid Therapeutics plans the phase I/II RENEWAL trial for Vasculitis (Treatment-experienced) in Germany (IV, Infusion) (CTIS2025-522853-21-01)
  • 08 Sep 2025 Genor Biopharma in collaboration with Ruijin Hospital plans a phase-0 trial for Systemic-scleroderma in September 2025 (Parenteral), (NCT07159009)
  • 20 Jun 2025 Clinical trials in Systemic scleroderma (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top